CNBX PHARMACEUTICALS INC.: 10-Q filed 2023-04-14

Name: CNBX PHARMACEUTICALS INC.: 10-Q filed 2023-04-14
Creator: CNBX PHARMACEUTICALS INC.

What CNBX PHARMACEUTICALS INC. reported in its quarterly report filed 2023-04-14 (fiscal Q2 2023): 28 published measures, 84 facts as tagged in accession 0001683168-23-002379.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-04-14
Fiscal period: fiscal Q2 2023
Accession: 0001683168-23-002379 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-02-28	462,052	USD
At 2022-08-31	811,166	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-02-28	-2,011,532	USD
At 2022-11-30	-1,974,293	USD
At 2022-08-31	-1,632,311	USD
At 2022-02-28	-648,028	USD
At 2021-11-30	802,708	USD
At 2021-08-31	1,805,915	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-02-28	47,748	USD
At 2022-08-31	117,515	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	-2,624,321	USD	90
2022-09-01 to 2023-02-28	-2,981,990	USD	181
2021-12-01 to 2022-02-28	-1,238,871	USD	90
2021-09-01 to 2022-02-28	-2,561,891	USD	181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-09-01 to 2023-02-28	-114,447	USD	181
2021-09-01 to 2022-02-28	-1,154,322	USD	181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-09-01 to 2023-02-28	19,978	USD	181
2021-09-01 to 2022-02-28	0	USD	181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2022-09-01 to 2023-02-28	24,702	USD	181
2021-09-01 to 2022-02-28	-513	USD	181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-02-28	-23,530,958	USD
At 2022-08-31	-20,548,968	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	1,962,999	shares	90
2022-09-01 to 2023-02-28	2,086,873	shares	181
2021-12-01 to 2022-02-28	1,226,185	shares	90
2021-09-01 to 2022-02-28	1,126,965	shares	181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	1,962,999	shares	90
2022-09-01 to 2023-02-28	2,086,873	shares	181
2021-12-01 to 2022-02-28	1,226,185	shares	90
2021-09-01 to 2022-02-28	1,126,965	shares	181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	-1.33	USD/shares	90
2022-09-01 to 2023-02-28	-1.42	USD/shares	181
2021-12-01 to 2022-02-28	-1.01	USD/shares	90
2021-09-01 to 2022-02-28	-2.27	USD/shares	181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	-1.33	USD/shares	90
2022-09-01 to 2023-02-28	-1.42	USD/shares	181
2021-12-01 to 2022-02-28	-1.01	USD/shares	90
2021-09-01 to 2022-02-28	-2.27	USD/shares	181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-02-28	353,217	USD
At 2022-08-31	436,792	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-09-01 to 2023-02-28	110,530	USD	181
2021-09-01 to 2022-02-28	530,662	USD	181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	-250,010	USD	90
2022-09-01 to 2023-02-28	-596,800	USD	181
2021-12-01 to 2022-02-28	-730,261	USD	90
2021-09-01 to 2022-02-28	-1,840,610	USD	181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-02-28	108,835	USD
At 2022-08-31	198,287	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-02-28	2,473,584	USD
At 2022-08-31	2,443,475	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	250,010	USD	90
2022-09-01 to 2023-02-28	596,800	USD	181
2021-12-01 to 2022-02-28	730,261	USD	90
2021-09-01 to 2022-02-28	1,840,610	USD	181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	12,328	USD	90
2022-09-01 to 2023-02-28	75,215	USD	181
2021-12-01 to 2022-02-28	330,576	USD	90
2021-09-01 to 2022-02-28	770,620	USD	181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-02-28	2,209,385	shares
At 2022-08-31	1,257,927	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-02-28	47,748	USD
At 2022-08-31	117,515	USD
At 2022-02-28	231,637	USD
At 2021-08-31	1,386,472	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-02-28	18,390,628	USD
At 2022-08-31	18,031,869	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-02-28	-330,933	USD
At 2022-08-31	-2,574,846	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2023-02-28	61,087	USD
At 2022-08-31	80,772	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	-2,624,321	USD	90
2022-09-01 to 2023-02-28	-3,041,860	USD	181
2021-12-01 to 2022-02-28	-1,605,661	USD	90
2021-09-01 to 2022-02-28	-3,209,892	USD	181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	237,683	USD	90
2022-09-01 to 2023-02-28	521,585	USD	181
2021-12-01 to 2022-02-28	399,685	USD	90
2021-09-01 to 2022-02-28	1,069,990	USD	181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2022-09-01 to 2023-02-28	83,575	USD	181
2021-09-01 to 2022-02-28	102,411	USD	181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2022-12-01 to 2023-02-28	20,987	USD	90
2022-09-01 to 2023-02-28	10,108	USD	181
2021-12-01 to 2022-02-28	-508,610	USD	90
2021-09-01 to 2022-02-28	-721,280	USD	181

Inspect the source

Entity: CNBX PHARMACEUTICALS INC. / CIK 0001343009
Captured: 2026-09-20T07:54:32.519Z
SEC response SHA-256: 915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))